Pfizer and Cipla, working with the American Cancer Society and Clinton Health Access Initiative, plan to steeply discount the prices of cancer medicines in Africa.
The two market access agreements with NY-based Pfizer and Mumbai-based Cipla promise to expand access to sixteen essential cancer treatment medications, including chemotherapies, in Ethiopia, Nigeria, Kenya, Uganda, Rwanda and Tanzania.
The agreements will set competitive prices on the meds, allowing African governments to realize substantial savings while improving the quality of available treatment. As reported by the NY Times, Pfizer will set prices just above its own manufacturing costs. Cipla said it would sell some pills for 50 cents and some infusions for $10.
Read the press release